The pharmacokinetics of antimicrobials in patients with obesity remains largely unknown, though it is likely that they diverge significantly from those of the non-obese. This would make the current dosing regimens for obese critically ill patients highly sub-optimal.

This multi-centre study will describe the pharmacokinetics of piperacillin, meropenem and fluconazole in critically ill obese patients.

Project members

Professor Jason Roberts

Chief Investigator and CRE lead

Professor Jeffrey Lipman

Chief Investigator

Associate Professor Andrew Udy

Associate Investigator